Scientific Abstracts (respectively PGA and PhGA) were rated on a 0-10 numeric scale, every 6 months during 2 years then at 3 years. Only patients with all data available for PGA and PhGA for each of the 6 visits were included. Repeated discordance was defined as an absolute difference |PGA-PhGA|≥3/10 for at least 3 of the 6 visits (i.e., at least half of the visits). Univariable and multivariable logistic models were used to determine if repeated discordance was associated at the 3 years timepoint, with prescription of TNFi, functional incapacity defined as HAQ>0.5, and remission defined as ASDAS-CRP<1.3. Results: Of 401 patients, mean age 34.6±8.7 years, mean symptoms duration 17.8±10.7 months, 219 (54.6%) were female and mean ASDAS-CRP at baseline 2.7±1.0. At 3 years 140 (34.9%) patients had been prescribed a TNFi, 172 (43.2%) had HAQ>0.5 and 89 (25.1%) were in remission. Over the 6 visits, mean PGA was higher than mean PhGA with a mean absolute difference of 0.8±2.2 points. Discordance concerned 110 (27.4%) patients at baseline and repeated discordance concerned 92 (22.9%) patients. In multivariable logistic regression, after adjusting on the others significant factors (which included MRI sacro-iliitis, HLA-B27 and ASDAS-CRP at baseline), repeated discordance was associated with more functional incapacity (61% vs 38%, odds ratio, OR 2. Background: Traditionally, radiographic imaging was used to describe morphological differences between various types of axial SpA (axSpA). The advent of MRI has advanced understanding of disease, enabled earlier diagnosis and visualization of structural changes, and facilitated the identification of non-radiographic axial SpA (nr-axSpA). The magnitude of the pathologic changes in the axial skeleton is used to quantify inflammatory and structural outcomes of clinical trials and treatment of patients with axSpA. Objectives: To examine the MRI morphology of sacroiliitis (SI) and vertebral corner lesions in patients with primary (1°, no psoriasis) and secondary (2°, with psoriasis) axSpA. Methods: This posthoc analysis was performed on data from patients with axSpA enrolled in the EMBARK trial (NCT01258738). Only patients with baseline MRI lesions were included. Symmetric and asymmetric SI, structural lesions, and corner inflammatory lesions were analyzed in 1°axSpA vs 2°axSpA patients. Data were analyzed using one-way analysis of variance for continuous parameters, chi-square tests, or Fisher's exact tests for categorical parameters. Results: The baseline demographics and disease characteristics between the 122 patients with 1°axSpA and 19 with 2°axSpA were similar. Asymmetric sacroiliitis was seen in significantly fewer 1°(43%) vs 2°(68%) axSpA patients. There were no differences in mean SpondyloArthritis Research Consortium of Abstract FRI0474 - Background: Diagnosis of axSpA is often delayed with 5-10 years. A robust biological disease marker is lacking and could decrease the current diagnostic delay. Two studies showed that serum anti-CD74 IgG antibodies are increased in SpA 1,2 . Objectives: To explore the value of anti-CD74 antibodies as diagnostic biomarker for axSpA in patients with early, chronic back pain. Methods: We tested the prevalence of anti-CD74 IgG and IgA antibodies in patients from the SPondyloArthritis Caught Early (SPACE) cohort by enzymelinked immunosorbent assay (ELISA). Patients from the SPACE cohort have chronic back pain for >3 months and ≤2 years with an onset <45 years. Results: We included 560 patients of the SPACE cohort, of whom 274 patients were diagnosed with axSpA by a rheumatologist at baseline. Anti-CD74 IgG levels did not differ between patients with and without axSpA (p=0.152, Table 1 ). Median anti-CD74 IgA levels (tested with either casein or BSA as a blocking buffer) were higher in patients with axSpA (both p<0.0001). Despite these differences at the group level, the diagnostic value of the anti-CD74 IgA antibodies was limited as shown by ROC analysis. The optimal cut off according to ROC analysis was an optical density (OD) of 0.875, providing a sensitivity of 38.3% and a specificity of 77.6%. In line with previous reports, further analysis revealed that total IgA levels were elevated in early axSpA patients vs. non-SpA early back pain patients (p=0.008). When correcting the level of anti-CD74 IgA for the level of total IgA, the differentiating capacity of anti-CD74 disappeared for casein but remained intact for BSA (casein: p=0.731, BSA: p=0.038). Additional analyses using the ASAS classification criteria rather than a clinical diagnosis of axSpA, a strict combination of clinical diagnosis and ASAS classification criteria (excluding patients fulfilling the ASAS axSpA criteria without a clinical diagnosis and vice versa) (Table 1 ) and using the clinical diagnosis at 1 year of follow-up yielded similar results.
Background: Diagnosis of axSpA is often delayed with 5-10 years. A robust biological disease marker is lacking and could decrease the current diagnostic delay. Two studies showed that serum anti-CD74 IgG antibodies are increased in SpA 1,2 . Objectives: To explore the value of anti-CD74 antibodies as diagnostic biomarker for axSpA in patients with early, chronic back pain. Methods: We tested the prevalence of anti-CD74 IgG and IgA antibodies in patients from the SPondyloArthritis Caught Early (SPACE) cohort by enzymelinked immunosorbent assay (ELISA). Patients from the SPACE cohort have chronic back pain for >3 months and ≤2 years with an onset <45 years. Results: We included 560 patients of the SPACE cohort, of whom 274 patients were diagnosed with axSpA by a rheumatologist at baseline. Anti-CD74 IgG levels did not differ between patients with and without axSpA (p=0.152, Table 1 ). Median anti-CD74 IgA levels (tested with either casein or BSA as a blocking buffer) were higher in patients with axSpA (both p<0.0001). Despite these differences at the group level, the diagnostic value of the anti-CD74 IgA antibodies was limited as shown by ROC analysis. The optimal cut off according to ROC analysis was an optical density (OD) of 0.875, providing a sensitivity of 38.3% and a specificity of 77.6%. In line with previous reports, further analysis revealed that total IgA levels were elevated in early axSpA patients vs. non-SpA early back pain patients (p=0.008). When correcting the level of anti-CD74 IgA for the level of total IgA, the differentiating capacity of anti-CD74 disappeared for casein but remained intact for BSA (casein: p=0.731, BSA: p=0.038). Additional analyses using the ASAS classification criteria rather than a clinical diagnosis of axSpA, a strict combination of clinical diagnosis and ASAS classification criteria (excluding patients fulfilling the ASAS axSpA criteria without a clinical diagnosis and vice versa) ( Table 1 ) and using the clinical diagnosis at 1 year of follow-up yielded similar results.
Conclusions: Serum anti-CD74 IgA antibody levels, but not serum anti-CD74 IgG levels, are elevated in patients with axSpA versus non-SpA with back pain of <2 years duration. However, ROC analyses revealed that these numerical differences are of limited diagnostic value in these patients with early back pain.
